Abstract:Abstract Abstract 4504 Bronchiolitis obliterans (BO), occurring beyond 3 months after allogeneic hematopoietic stem cell transplantation (allo-HSCT), has been recognized as a late-onset noninfectious pulmonary complication associated with substantial morbidity and mortality. Some reports have described this complication with different incidence, associated risk factors, prognoses and therapeutic strategies. However, up to date, there is no unified understanding with respect to BO worldwide. In this study, we retrospectively analyzed the incidence, risk factors, clinical characteristics, management approaches and prognosis of BO among unrelated donor allo-HSCT recipients in our transplant center, aiming to improve cognition, reduce misdiagnose and dicrease motality in the future. Between June 2005 and May 2009, 117 patients underwent unrelated donor allo-HSCT while 98 patients who survived and were free of disease for more than 3 months after engraftment were enrolled. Myeloablative conditioning therapies for HLA-mathced transplant included busulfan-Cyclophosphamide (Bu-Cy) based regimens. In HLA-mismatched transplant, anti-thymocyte globulin (ATG) were added in addition to Bu-Cy based regimen. Patients were offered nonmyeloablative conditioning regimens when they were ineligible for myeloablative preparative regimens with fludarabine-based regimens including fludarabine, ATG and Bu. The diagnosis of BO was based on pulmonary function abnormalities, chest high-resolution CT (HRCT) findings and exclusion from respiratory infections. Management approaches for BO included immunosuppressive agents, azithromycin and symptomatic support. Some patients were further treated with etanercept (anti-tumour necrosis factor). In total 14 of the 98 patients (14.3%) developed BO at a median interval of 307.5 days post engraftment (range, 188–1316 days). Pulmonary function tests showed a decline in FEV1/FVC to a median interval of 0.51 (0.33-0.69) and FEV1 to 32% (17-46.2%) of predicted at BO diagnosis. Chest HRCT of BO patients showed areas of air trapping on expiratory views (71.4%), hyperinflation or bronchial dilatation (64.3%). All the 14 patients (100%) with BO complicated with chronic GVHD versus 41 of the 84 patients(48.6%) without BO (P<0.05). In total 1 of the 14 patients (7.1%) with BO underwent ATG-containing conditioning regimen versus 30 of 84 patients (35.7%) without BO (P<0.05). Multivariate analysis showed that primary disease type, donor and recipient's sex or age, stem cell type, myeloablative or nonmyeloablative conditioning regimen, aGVHD complication and HLA-disparities were not associated with the incidence of BO statistically. The prognoses of most BO patients were poor. In total only 4 of the 14 patients got improved and 3 were stable due to treatment while 2 were progressive and 5 (35.7%) died. Pulmonary failure was the leading cause of death for BO patients. In non-BO group, 23 of the 84 patients (28.6%) died, with a non-relapse mortality of 15.5% and infection became the leading cause of death. The non-relapse mortality in BO patients was higher than that in non-BO patients although there was no statistical significance (P>0.05). In all, our results demonstrated that chronic GVHD and conditioning regimen containing ATG, but not others which had been reported to be related with BO, were two risk factors associated with BO and the prognosis was extremely poor. More clinical trials and basic researches should be carried out to allow prospective identification of patients at greatest risk and early new therapeutic intervention to finally improve the survival of patients in this group. Disclosures: No relevant conflicts of interest to declare.

Effects of Normobaric Hypoxia Equivalent to 2,000-m Altitude on Sleep and Physiological Conditions of Athletes: A Study Using Sheet-Type Sensor

Management of Busulfan-Induced Lung Injury in Pediatric Patients with High-Risk Neuroblastoma

Busulfan and Cyclophosphamide for Hemopoietic Stem Cell Transplantation from Related and Unrelated Donors in Patients with Myelodysplastic Syndrome

Bronchiolitis Obliterans Following Unrelated-Donor Allogeneic Hematopoietic Stem Cell Transplantation.

Evaluating the Efficacy, Toxicity and Pharmacokinetic Profile of Oral Busulfan in Allogeneic Stem Cell Transplant Patients

Review of the Pharmacokinetics and Pharmacodynamics of Intravenous Busulfan in Paediatric Patients

The Correlation Between Busulfan Exposure and Clinical Outcomes in Chinese Pediatric Patients: A Population Pharmacokinetic Study

Effect of Age on the Pharmacokinetics of Busulfan in Patients Undergoing Hematopoietic Cell Transplantation; an Alliance Study (CALGB 10503, 19808, and 100103)

Impact of busulfan versus treosulfan dose intensity in myelofibrosis undergoing hematopoietic cell transplantation

Pharmacokinetics of intravenous busulfan as condition for hematopoietic stem cell transplantation: comparison between combinations with cyclophosphamide and fludarabine

Pulmonary complications of bone marrow transplantation

Identification of risk factors for bronchiolitis obliterans syndrome after reduced toxicity conditioning before hematopoietic cell transplantation

[The Efficacy and Safety of Modified Busulfan/fludarabine Conditioning Regimen in Elderly or Drug-Intolerable Patients with Hematologic Malignancies].

Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality

Evaluation of risk for bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation with myeloablative conditioning regimens

Age and dose dependent changes to the bone and bone marrow microenvironment after cytotoxic conditioning with busulfan

Identification of Deterministic Switched ARX Systems via Identification of Algebraic Varieties

Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review

Therapeutic Drug Monitoring of Busulfan in Patients Undergoing Hematopoietic Cell Transplantation: A Pilot Single-Center Study in Taiwan

Pulmonary hypertension in the intensive care unit after pediatric allogeneic hematopoietic stem cell transplant: incidence, risk factors, and outcomes

Impact of age on safety of Busulfan-Melphalan followed by autologous hematopoietic stem-cell transplantation versus standard chemotherapy in the patients of the EURO-E.W.I.N.G. 99 and Ewing 2008 clinical trials